Testing QLS2313 for blood cancers that have returned or not responded
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental drug, QLS2313, for people with certain types of blood cancer (B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma) that have not gotten better with other treatments. The goal is to see if the drug is safe and works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma that has returned or not responded to treatment.
- You have no standard treatment options left that your doctor thinks will work.
- Your cancer can be measured by scans or tests.
- You are generally well enough to be up and about at least half the day (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLS5132, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called QLS5133 for people with advanced solid tumors that have not responded to other treatments. The drug is given alone, and the study aims to see if it is safe and effective.
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
This study tests a new experimental drug called QLS5316 for people with advanced solid tumors that have not responded to standard treatments. The drug works like a 'smart bomb'—it seeks out and delivers medicine directly to cancer cells.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
Hear when a new Relapsed/Refractory Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.